2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Molecular Testing, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Palliative Care, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Practice Models, Quality of Care, Systems-Based Hematology, Diseases, Infectious Diseases, Bacterial, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

3360 Monocytic AML and respiratory failure in the peri-induction period: Incidence, timing, and prognostic significance

Neha Puttagunta, MD, Kunal Shah, MD2, Angela Gupta, MD3, Bradley Goldberg, MD4, Jonathan Kolitz, MD5, Erin Jou, MD6, Stephanie Boisclair, MD7, Douglas E Gladstone, MD8, David W Chitty, MD9
1 Northwell, New Hyde Park, United States
2 Northwell Health Cancer Institute, Lake Success, United States, Northwell, New Hyde Park, United States
3 Northwell, New Hyde Park, United States
4 Northwell Health Cancer Institute, Lake Success, United States, Northwell, New Hyde Park, United States
5 Northwell Health Cancer Institute, Lake Success, United States, Northwell, New Hyde Park, United States
6 Northwell Health Cancer Institute, Lake Success, United States, Northwell, New Hyde Park, United States
7 Northwell Health Cancer Institute, Lake Success, United States, Northwell, New Hyde Park, United States
8 Northwell Health Cancer Institute, Lake Success, United States, Northwell, New Hyde Park, United States
9 Northwell Health Cancer Institute, Lake Success, United States, Northwell, New Hyde Park, United States

Background
Acute myeloid leukemia (AML) with monocytic differentiation possesses a unique clinicopathologic profile marked by extramedullary tissue involvement and hyper-inflammatory signaling that directly predisposes patients to early, life-threatening respiratory failure. Importantly, the incidence, timing, and prognostic significance of respiratory compromise during induction therapy have not been systematically characterized. We evaluated the respiratory support requirements and their relationship to clinical outcomes in a contemporary cohort of newly diagnosed monocytic AML patients in the first 90 days from initial presentation. 

Methods
We performed a retrospective single-center cohort study of 173 consecutive adults with monocytic AML, managed by a tertiary leukemia service between 2016 and 2026. Subtypes included myelomonocytic/FAB M4, monoblastic/M5a, and monocytic/M5b subtypes. Overall survival was calculated from diagnosis date (peripheral blood flow cytometry or bone marrow evaluation) to last known follow-up. Oxygen requirements, pulmonary complications, and mortality were assessed over the first 90 days, capturing the intended induction period of various treatment modalities. Oxygen requirements were categorized by initial and peak respiratory support: room air, low-flow nasal cannula (NC), advanced non-invasive support (ANIS; Venturi mask, non-rebreather, high-flow NC, and non-invasive positive pressure ventilation), or invasive mechanical ventilation (IMV). Clinical characteristics, laboratory parameters, molecular features, treatment, and survival were analyzed using Kaplan-Meier estimates and age-adjusted regression models with false discovery rate correction. 

Results 
Among 173 patients (median age 74 years, 54% male, 39.3% non-Caucasian), 84% underwent induction therapy with either intensive 7+3 (16%), HMA + venetoclax (52%), HMA alone (12%) or other (4%) regimens. Supplemental oxygen was required in 65% of patients; peak supplementation included 28% NC, 21% ANIS, and 15% IMV. Median time from admission to first oxygen requirement was 2 days (range 0–59).  Of the 112 oxygen-requiring patients, 36% required oxygen on or directly before admission, rising cumulatively to 54% by 48 hours and 71% by one week. Among the 63 patients reaching ANIS or IMV, 51% progressed within 24 hours of first O2 use. Relative to induction, 62% (of 112) required oxygen prior to definitive front-line therapy including a subgroup (21%) who expired prior to receiving induction therapy.  

Mortality from diagnosis rose sharply above NC at 30/60/90 days: room air 5/7/8%, NC 12/18/24%, advanced non-invasive 24/43/51% and invasive ventilation 62/73/73%. Of the 26 patients who were intubated, only 5 were successfullyextubated. Relative to room air, need for low-flow NC O2 conferred no significant excess 90-day mortality risk (HR 2.78; 95% CI, 0.98–7.91), in contrast to ANIS (HR 7.15;2.66–19.25) and IMV (HR 17.80; 6.51–48.68). Median survival following peak oxygen requirement was 18 days after advanced support vs 379 days after NC alone (48% vs 81% alive at day 30; HR 2.49, 1.53–4.08). Death within the first 30 days of diagnosis occurred in 20% (34/173) patients; this includes 74% (20/27)of the patients who never received induction therapy. Pre-treatment WBC count >100 (k/mcL) was associated with increased 30/60/90-day mortality (age-adjusted HR 7.37, 95% CI 3.62–15.02; 5.25, 2.80–9.83; and 4.94, 2.72–8.96) and an increased incidence of IMV at 50% (13/26) vs. 9% (13/147) in those under the threshold (OR 10.31, 95% CI 3.96–26.83). Laboratory antecedents of advanced support included WBC >50 (OR 2.84), WBC >100 (OR 5.10), creatinine >1.5 mg/dL (OR 2.77) and LDH>500 U/L (OR 2.48). No recurrent AML molecular abnormality predicted any respiratory endpoint or short-term mortality.  

Conclusion 
Respiratory failure is a common, early manifestation of monocytic AML that frequently precedes chemotherapy and identifies a high-risk clinical phenotype independent of molecular risk. Presenting hyperleukocytosis was associated with higher incidence of respiratory failure, need for IMV and early mortality. Early oxygen supplementation with advanced non-invasive and invasive support was associated with significantly higher mortality in the peri-induction period up to 90 days from initial presentation. Presenting WBC count and evolving oxygenation requirements are readily available for bedside markers for risk stratification and warrant further study.

Neha Puttagunta, MD: No relevant conflicts of interest to declare.